Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
63°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharmaceuticals, Inc. - Common Stock
(NQ:
SUPN
)
31.26
+0.09 (+0.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Supernus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
Today 5:01 EDT
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
3 Small-Cap Stocks Skating on Thin Ice
March 13, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
March 04, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Earnings Scheduled For February 25, 2025
February 25, 2025
Via
Benzinga
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
March 04, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
February 27, 2025
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know.
Via
StockStory
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
February 26, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.
Via
StockStory
Viatris Earnings: What To Look For From VTRS
February 26, 2025
Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect.
Via
StockStory
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
February 26, 2025
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Via
StockStory
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
February 25, 2025
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6% year on year to $174.2 million. On the...
Via
StockStory
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
February 24, 2025
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know.
Via
StockStory
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
February 19, 2025
Via
Benzinga
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
February 19, 2025
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on its future.
Via
Benzinga
Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
February 19, 2025
Via
Benzinga
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
February 19, 2025
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
February 18, 2025
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks
January 06, 2025
The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Screening For Black Friday Bargains In The Stock Market
December 03, 2024
Via
Benzinga
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
September 11, 2024
Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million.
Via
Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
September 11, 2024
Via
Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
September 11, 2024
Via
Benzinga
For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals.
August 06, 2024
In a market where value is scarce, SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
July 19, 2024
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.
Via
InvestorPlace
NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
July 05, 2024
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents.
June 14, 2024
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) stands out as a stock that provides good value for the fundamentals it showcases.
Via
Chartmill
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
May 08, 2024
SUPN stock results show that Supernus Pharmaceuticals missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
April 08, 2024
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 08, 2024
Via
Benzinga
Biotechnology And Healthcare, A Bit Of A Lull
March 25, 2024
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors.
Via
Talk Markets
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.